Y. Summers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Y. Summers has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Carla Visseren-Grul
Eli Lilly and Company, 3528 BJ Utrecht, The Netherlands
2 shared publications A. Argiris
1 shared publicationA. Baird
1 shared publicationA. Casbard
1 shared publicationA. Falco
1 shared publicationA. Hollebecque
1 shared publication
Latest Publications
- Top Cited Papers
- 1 March 2016
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 44, 42-50
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
- 1 March 2016
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 44, 42-50
Top Cited PapersCisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv433-iv434
Feasibility of Home Delivery (Hd) of Maintenance Pemetrexed (Pem) Therapy for Advanced Nonsquamous Non Small Cell Lung Cancer (Adv Nsqnsclc)
Aim: Some patients with adv nsqNSCLC may not need hospital-based chemotherapy. This study evaluated the feasibility and adherence to HD of maintenance PEM therapy in these patients. PEM is suitable for HD due to its favorable safety profile and ease of use (10-minute i.v. infusion). Methods: Exploratory, prospective, single-arm, Phase 2 study in adv nsqNSCLC patients, ECOG performance status 0 or 1 without progression after 4 induction cycles of platinum doublet. The first cycle of PEM (500mg/m2) was hospital administered, further cycles as HD until progressive disease or discontinuation. Feasibility was assessed by the adherence rate to HD (probability of reversion to hospital administration or discontinuation due to HD) as primary endpoint, and by health related quality of life (HRQoL) (EQ-5D, lung cancer symptom scale [LCSS]), satisfaction with HD, Overall Survival (OS), and safety. Results: 52 patients (UK/Sweden) had a median of 4 (range 1-19) maintenance PEM cycles. Adherence rate up to Cycle 6 was 98% (95% CI: 86.4%, 99.7%). All but 2 patients remained on HD. 1 patient discontinued after Cycle 1 (before first HD, [safety concerns]) and 1 patient after Cycle 6 (investigator decision [non-compliance with oral dexamethasone]). 82% (31/38) patients preferred home treatment and in 90% (28/31) of cases, physicians were satisfied with distant patient management. During HD Cycles 2-4 mean change from baseline ranged from 3-8 for EQ-5D VAS and from –5 to –8 for LCSS average symptom burden index. The 6-month OS rate was 73% (95% CI: 58%, 83%). 1 patient had an HD related AE (device related infection Grade [G] 2) and 1 patient died (possibly drug related atypical pneumonia). Conclusions: HD of maintenance PEM therapy in adv nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL. Physicians were satisfied with distant patient management. Community-based clinical research requires specific consideration and resource allocation. Disclosure: M.C. Nicolson: The author has a personal specific interest in terms of advisory board work and also paid lectures for Lilly; also non-personal specific in terms of research support and meeting attendance support; C.M. Visseren-Grul: Lilly Employee The author declares no conflict of interest; M. Lorenzo: Lilly Employee The author declares no conflict of interest; Y. D'Yachkova: Lilly Employee The author declares no conflict of interest; N. Bourayou: Lilly Employee The author declares no conflict of interest. All other authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv433-iv434
Feasibility of Home Delivery (Hd) of Maintenance Pemetrexed (Pem) Therapy for Advanced Nonsquamous Non Small Cell Lung Cancer (Adv Nsqnsclc)
Aim: Some patients with adv nsqNSCLC may not need hospital-based chemotherapy. This study evaluated the feasibility and adherence to HD of maintenance PEM therapy in these patients. PEM is suitable for HD due to its favorable safety profile and ease of use (10-minute i.v. infusion). Methods: Exploratory, prospective, single-arm, Phase 2 study in adv nsqNSCLC patients, ECOG performance status 0 or 1 without progression after 4 induction cycles of platinum doublet. The first cycle of PEM (500mg/m2) was hospital administered, further cycles as HD until progressive disease or discontinuation. Feasibility was assessed by the adherence rate to HD (probability of reversion to hospital administration or discontinuation due to HD) as primary endpoint, and by health related quality of life (HRQoL) (EQ-5D, lung cancer symptom scale [LCSS]), satisfaction with HD, Overall Survival (OS), and safety. Results: 52 patients (UK/Sweden) had a median of 4 (range 1-19) maintenance PEM cycles. Adherence rate up to Cycle 6 was 98% (95% CI: 86.4%, 99.7%). All but 2 patients remained on HD. 1 patient discontinued after Cycle 1 (before first HD, [safety concerns]) and 1 patient after Cycle 6 (investigator decision [non-compliance with oral dexamethasone]). 82% (31/38) patients preferred home treatment and in 90% (28/31) of cases, physicians were satisfied with distant patient management. During HD Cycles 2-4 mean change from baseline ranged from 3-8 for EQ-5D VAS and from –5 to –8 for LCSS average symptom burden index. The 6-month OS rate was 73% (95% CI: 58%, 83%). 1 patient had an HD related AE (device related infection Grade [G] 2) and 1 patient died (possibly drug related atypical pneumonia). Conclusions: HD of maintenance PEM therapy in adv nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL. Physicians were satisfied with distant patient management. Community-based clinical research requires specific consideration and resource allocation. Disclosure: M.C. Nicolson: The author has a personal specific interest in terms of advisory board work and also paid lectures for Lilly; also non-personal specific in terms of research support and meeting attendance support; C.M. Visseren-Grul: Lilly Employee The author declares no conflict of interest; M. Lorenzo: Lilly Employee The author declares no conflict of interest; Y. D'Yachkova: Lilly Employee The author declares no conflict of interest; N. Bourayou: Lilly Employee The author declares no conflict of interest. All other authors have declared no conflicts of interest.
- Open Access
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix492-ix498
Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)
Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a topoisomerase inhibitor, in the treatment of refractory or resistant SCLC.
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix492-ix498
Open AccessPhase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)
Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a topoisomerase inhibitor, in the treatment of refractory or resistant SCLC.